May Health Company

AblaCare has developped an innovative solution for Polycystic Ovary Syndrome (PCOS) related infertility, designed to provide women with more natural and less medicalized pregnancy. PCOS is the #1 cause of female infertility. Since 2017, they have been working on developing an innovative solution, aiming to restore ovulation in patients through a simple, one-time, durable, minimally invasive treatment. The Procedure can be performed in a clinic setting, without General Anesthesia, using the same minimally invasive access commonly used by fertility physicians for IVF.
Industry: Reproductive Health & Contraception
Headquarters: Paris, Ile-de-France, France
Founded Date: 01-01-2017
Employees Number: 1-10
Funding Status: Early Stage Venture
Investors Number: 2
Total Funding: $11,204,444
Estimated Revenue: $1M to $10M
Last Funding Date: 2019-07-09
Last Funding Type: Series A

Visit Website
contact@ablacare.com
https://twitter.com/AblaCare
Register and Claim Ownership